BLISSGVS — Bliss GVS Pharma Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapHigh Flyer

Annual income statement for Bliss GVS Pharma, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	C2020 March 31st	2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IAS	IAS	IAS	IAS	IAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	6,893	5,772	7,475	7,516	7,702
Cost of Revenue
Gross Profit	2,435	2,402	3,482	3,431	3,777
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	5,920	4,878	7,200	6,529	6,752
Operating Profit	973	894	274	986	950
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	1,290	1,041	542	1,061	1,169
Provision for Income Taxes
Net Income After Taxes	953	740	231	767	816
Minority Interest
Net Income Before Extraordinary Items
Net Income	973	685	150	709	755
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	973	685	150	709	755
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	10.4	6.5	4.42	6.69	9.02
Dividends per Share